D
Decibel Therapeutics
Pioneering inner ear research to deliver life-changing medicines for hearing and balance
About Decibel Therapeutics
Decibel Therapeutics is a biotechnology company focused on developing novel therapies for hearing loss and tinnitus. The company operates in the healthcare and pharmaceutical market, primarily serving patients with auditory and balance disorders. Decibel Therapeutics employs a unique approach by translating scientific advances in inner ear biology into groundbreaking treatments. Their business model revolves around extensive research and development (R&D) to create proprietary drugs, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships, and potentially licensing agreements.
Decibel Therapeutics' pipeline includes a broad strategy aimed at both protecting and restoring hearing, addressing a significant unmet need in the medical community. The company leverages cutting-edge research in genetics, genomics, bioinformatics, and microsurgery to fuel its drug development efforts. Their team comprises experts in pharmacology, translational medicine, and manufacturing, with a track record of filing numerous Investigational New Drug (IND) applications and launching successful therapies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Boston, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 62.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2023 | $109M | — | Regeneron Pharmaceuticals | ↗ |
| SERIES DOther financing | Nov 2020 | $82M | $329M | BlackRock · Third Rock Ventures · Janus Henderson Investors · S-Cubed Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Decibel Therapeutics is 400 monthly website visits, down 90% over the last three months. Decibel Therapeutics's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
SR One
Third Rock Ventures
GSK
Series B and later10 investors entered at this stage
Bessemer Venture Partners
OrbiMed
BlackRock
Janus Henderson Investors
S-Cubed Capital
Casdin Capital
Foresite Capital
Citadel
The Sobrato Organization
Samsara BioCapital
Other known investors1 additional known investor
Regeneron Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Decibel Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Decibel Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.